; (ii) penalties or other corrective actions imposed with respect to the requirements described in clause (i); (iii) the prevalence of the application of performance measures in network pharmacy agreements, and the manner in which such measures are applied, including variation based on the type of pharmacy, the type of drug dispensed, and the services required to manage and dispense such drug; (iv) the extent to which the performance measures and related criteria applied under network agreements vary among similar types of pharmacies within a single network, and the extent to which the application of such measures or criteria differ between pharmacies— (I) affiliated with a pharmacy benefit manager, a PDP sponsor offering a prescription drug plan, or an MA organization offering a MA–PD plan; and (II) those not affiliated with an entity described in subclause (I); (v) patterns and trends in the performance measures applied under pharmacy network agreements, including if the measure is being used in accordance with published measure specifications which have been validated and tested, if the measure is being used according to licensing agreements with measure stewards, and the level of attribution and attribution criteria; (vi) the extent to which performance measures result in incentive payments, fees, price concessions, or other forms of remuneration between pharmacies and PDP sponsors or MA organizations (or pharmacy benefit managers acting on their behalf), including an analysis of which measures most often result in incentive payments to pharmacies (and the general amount of such payments) and which measures most often result in remuneration paid by pharmacies to other entities (and the general amount of such payments); (vii) variation in the type of remuneration (as described in clause (vi) resulting from the application of performance measures, including between different types of pharmacies, different types of drugs dispensed, and affiliation status of pharmacies (as described in clause (iv))